Pancreatic Cancer Action Network praises President Obama for new Precision Medicine Initiative

NewsGuard 100/100 Score

"The Pancreatic Cancer Action Network applauds President Obama for his new Precision Medicine Initiative, and for making an important investment to advance cancer research and arm the scientific and medical community with the cutting edge tools and resources needed to fight cancer. This is especially welcome news for patients fighting pancreatic cancer who face a five-year survival rate of just seven percent.

Personalized medicine for pancreatic cancer is in its early stages, but the Pancreatic Cancer Action Network is leading the rapidly growing field. We recognize, as President Obama highlighted, that the "one-size-fits-all" approach does not work for pancreatic cancer and recently launched Know Your Tumor, a personalized medicine service available through our patient services program. In addition to providing molecular profiling that may help a patient's oncologist determine the best treatment options, we will collect tumor information from thousands of pancreatic cancer patients to assist with future research and development of new therapies and diagnostics for pancreatic cancer.

We stand ready to partner with the administration, the National Cancer Institute and cancer community at large to transform the way we treat cancer and to advocate for the federal funding increases necessary to fully deliver on the promise of the Precision Medicine Initiative."

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
MONET: New AI tool enhances medical imaging with deep learning and text analysis